<info type="DiseaseOrPhenotypicFeature">Necrotising fasciitis</info> after <info type="ChemicalEntity">bortezomib</info> and <info type="ChemicalEntity">dexamethasone</info>-containing regimen in an elderly patient of <info type="DiseaseOrPhenotypicFeature">Waldenstrom macroglobulinaemia</info>.

<info type="ChemicalEntity">Bortezomib</info> and high-dose <info type="ChemicalEntity">dexamethasone</info>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with <info type="DiseaseOrPhenotypicFeature">B-cell malignancies</info>. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a <info type="SequenceVariant">76-year-old</info> man with <info type="DiseaseOrPhenotypicFeature">Waldenstrom macroglobulinaemia</info> who suffered <info type="DiseaseOrPhenotypicFeature">necrotising fasciitis</info> without <info type="DiseaseOrPhenotypicFeature">neutropenia</info> after the combination treatment with <info type="ChemicalEntity">bortezomib</info>, high-dose <info type="ChemicalEntity">dexamethasone</info> and <info type="ChemicalEntity">rituximab</info>. Despite immediate intravenous antimicrobial therapy, he succumbed <info type="SequenceVariant">23 h</info> after the onset. Physicians should recognise the possibility of fatal bacterial infections related to <info type="ChemicalEntity">bortezomib</info> plus high-dose <info type="ChemicalEntity">dexamethasone</info> in elderly patients, and we believe this case warrants further investigation.